First Berlin Issues Updated Research Report on Callisto with Share Price Target of $2.50 and Buy Rating; Independent German Based Equity Research House Reiterates Key Messages Following Recent Callisto Financing.
Business Wire (February 13, 2006)
Permanent Link:
http://vlex.com/vid/berlin-callisto-reiterates-messages-54954739
Id. vLex: VLEX-54954739
Acceda a este documento
y pruebe vLex GRATIS durante 3 días
First Berlin Issues Updated Research Report on Callisto with Share Price Target of $2.50 and Buy Rating; Independent German Based Equity Research House Reiterates Key Messages Following Recent Callisto Financing.
NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced that a leading independent, First Berlin Equity Research, has issued an updated research report projecting a $2.50 sh...
Try vLex for FREE for 3 days
Access legal information from United States including:
- Constitutions
- Forms and Contracts
- Legal Books and Journals
- Case Law
- News and Business
- Regulations
- U.S. Code
Try vLex without any commitment for 3 days and see why you need it.
3
days of Free Access
If you are already a vLex customer, Access Here
